Close. He serves as a Director of Myriad Genetics, Inc., Dicerna Pharmaceuticals, Inc., Delcath Systems, Inc., and several private companies. PRINCETON, N.J., June 5, 2017 /PRNewswire/ -- Braeburn Pharmaceuticals, Inc. (Braeburn) announced today that Michael M. Derkacz has been named as President and Chief Executive Officer and joins Braeburn's Board of Directors. Other executives include Louis Ricigliano, Chief Financial Officer; Paul Johnson, Chief Commercial Officer. Braeburn Pharmaceuticals appoints Mike Derkacz to its Board of Directors as CEO September 11, 2018 June 5, 2017 by Talent4Boards Team – USA, NJ – Braeburn Pharmaceuticals, Inc. (NASDAQ:BBRX), announced today that Michael M. Derkacz has been named as President and Chief Executive Officer and joins Braeburn’s Board of Directors. Patrick J. Kennedy is a former member of the U.S. House of Representatives and the nation’s leading political voice on mental illness, addiction, and other brain diseases. Mike led the launch of Copaxone 40 mg, considered one of the most successful product introductions in the multiple sclerosis category and within the industry. Braeburn Pharmaceuticals, Inc. (Braeburn) announced today that Mike Derkacz has been named as President and Chief Executive Officer, and joins Braeburn’s Board of Directors. Braeburn Pharmaceuticals's key executives are Mike Derkacz, Louis Ricigliano and Paul Johnson. Braeburn Pharmaceuticals Names Mike Derkacz as President and CEO, former Head of CNS and Pain Therapeutics for Teva Pharmaceuticals, Braeburn President and CEO, Behshad Sheldon, steps down from Company and Board of Directors – Princeton, New Jersey — June 5, 2017, Braeburn Pharmaceuticals, Inc. (Braeburn) announced today that Mike Derkacz has been named as President and Chief Executive Officer, and joins Braeburn’s Board of Directors. “Braeburn represents a compelling and unique opportunity to make an important difference for patients suffering serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia,” noted Mike Derkacz. Braeburn’s commercial product, Probuphine® (buprenorphine) implant was approved by the FDA in May 2016. Prior to that, he was President, North America, of Dr. Reddy’s Laboratories. … Dr. Eisenberg joined Lilly in 1998 in Cardiovascular Discovery and, subsequently, was VP of General Medicine, and then Drug Safety. Behshad Sheldon, Braeburn president and CEO They noted that Braeburn’s recruitment to North Carolina was made possible in part by a performance-based grant of up to $100,000 from the One North Carolina Fund. Braeburn President and CEO, Mike Derkacz shared the Company's commitment to expanding opioid use disorder (OUD) treatment options through cutting edge research and improving access to Medication Assisted Therapy (MAT), in alignment with the HHS five-point strategy to … Braeburn Pharmaceuticals's President & CEO, Director is Mike Derkacz. Dr. Jerry Karabelas has held a number of senior executive positions in major pharmaceutical companies, including Head of Healthcare and CEO of Worldwide Pharmaceuticals for Novartis AG, where he had full responsibility for Novartis Pharma and Ciba Vision, as well as strategic and operational leadership of R&D. A biopharmaceutical executive with 25 years of commercial experience and proven success, most recently he was Senior Vice President and Head of Global Central Nervous System (CNS) and Pain Therapeutic Areas for Teva Pharmaceuticals (Teva). He currently serves as the Non-Executive Chairman of Lantheus Medical Imaging as well as a Healthcare Industry Executive for Avista. He was President and CEO of Neose Technologies, Inc., and also held R&D and marketing positions at Eli Lilly, Abbott and Searle. From 2002 – 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides. When was Braeburn Pharmaceuticals founded? The partnership with Braeburn Pharmaceuticals is a strong platform for the further global development of this new asset," said Fredrik Tiberg, President & CEO, Camurus. Braeburn’s investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Dr. Malamut brings to Braeburn more than 25 years of pharmaceutical and clinical leadership experience at emerging and leading biopharmaceutical companies. | COM-1002 January 2019. as Chief Medical Officer. Our leadership team is committed to our mission to help fight the opioid crisis. Close. Paul Eisenberg, M.D., M.P.H. Prior to Lantheus and Osmotica, Brian held the position of President and Chief Executive Officer and member of the Board of Directors of Fougera Pharmaceuticals Inc. Braeburn Pharmaceuticals' President and CEO, Behshad Sheldon, was also selected as a bronze award winner in the category of "Best Female Executive of the Year." “Mike is an accomplished and highly successful commercial leader, with deep expertise in launching new products, creating highly effective teams and focused organizational leadership,” said Seth L. Harrison, M.D., Chairman of Braeburn. 24 Ratings. News | Careers | Terms of Service | Privacy Policy, © 2020 Braeburn Inc. All rights reserved. braeburnpharma@mslgroup.com, News | Careers | Terms of Service | Privacy Policy, © 2020 Braeburn Inc. All rights reserved. A free inside look at Braeburn salary trends based on 9 salaries wages for 8 jobs at Braeburn. Braeburn Pharmaceuticals has developed an implantable version of opioid maintenance drug buprenorphine to help addicts stay off prescription pain killers and heroin. Braeburn Pharmaceuticals was founded in 2012. Who are Braeburn Pharmaceuticals key executives? Braeburn Resubmits New Drug Application for CAM2038 for Opioid Use Disorder. A biopharmaceutical executive with 25 years of commercial experience and proven success, most recently he was Senior Vice President and Head of Global Central Nervous System and Pain … MSLGROUP Phone 781-684-0770 Founded in 2012, Braeburn Pharmaceuticals is transitioning their manufacturing headquarters to North Carolina’s Research Triangle Park in a move that presents an opportunity to consolidate laboratory, manufacturing, and administrative functions under one roof, supporting the collaborative research culture of the organization. In 2005 he joined Amgen where he was SVP of Global Regulatory and Safety; and in 2014 became SVP of Global Medical and Chief Medical Officer. “With a broad portfolio of products, utilizing innovative technologies, Braeburn is poised to lead the way at a time when there is universal alignment among physicians, patients, payers, and the U.S. Government around the high sense of urgency to provide novel and effective treatments for those suffering from addiction. Ms. Sheldon has more than 25 years of experience leading pharmaceutical development and commercialization in the United States and globally. How many employees does Braeburn Pharmaceuticals have? SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/29/13 -- Titan Pharmaceuticals, Inc. (OTCBB: TTNP) announced today that it has entered into an amendment to its license agreement with Braeburn Pharmaceuticals Sprl for the exclusive commercialization rights in the U.S. and Canada to the investigational product Probuphine®, … Braeburn Pharmaceuticals's key executives are Mike Derkacz, Louis Ricigliano and Paul Johnson. Braeburn’s pipeline products are at various stages of clinical development and include weekly and monthly CAM2038, subcutaneous injection depot formulations of buprenorphine, being investigated in opioid addiction and pain, BB0417 buprenorphine/granisetron injectable for acute pain, and BB0817, six-month risperidone implant being investigated in schizophrenia. A biopharmaceutical executive with 25 years of commercial experience and proven success, most recently he was Senior Vice President and Head of Global Central Nervous System (CNS) and Pain Therapeutic Areas for Teva … Braeburn Pharmaceuticals said last week that it named Michael Derkacz as president and CEO of the buprenorphine implant-maker. "The positive results from this study, coupled with the earlier reported positive results from the pivotal Phase 3 efficacy trial, enable our teams to finalize regulatory submissions seeking approval in the U.S., Europe and other key global markets," said Behshad Sheldon, President and CEO of Braeburn Pharmaceuticals. ... the CEO of Braeburn… He was appointed Professor of Medicine and also was the Director of the Cardiac Intensive Care Unit at Barnes-Jewish Hospital. Patrick has since founded The Kennedy Forum, which leads a national dialogue on transforming mental health and addiction care delivery by uniting mental health advocates, business leaders, and government agencies, and co-founded One Mind, a global leader in open science collaboration in brain research. Braeburn Pharmaceuticals said last week that it named Michael Derkacz as president and CEO of the buprenorphine implant-maker. She currently also serves as the President and Chief Executive Officer of Braeburn Pharmaceuticals, Inc., or Braeburn, a portfolio company of … About Braeburn Pharmaceuticals Braeburn Pharmaceuticals, an Apple Tree Partners company, is a commercial-stage pharmaceutical company delivering individualized medicine in … Dr. Seth Harrison is the managing partner of Apple Tree Partners and serves as Executive Chairman of Braeburn Pharmaceuticals. 6/12/2018 Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. A biopharmaceutical executive with 25 years of commercial experience and proven success, most recently he was Senior Vice President and Head of Global Central Nervous System (CNS) and Pain Therapeutic Areas for Teva … Most recently, Jerry has chaired the boards of several biopharmaceutical companies, including Human Genome Sciences, Inc., Vanda Pharmaceuticals, Inc. and SkyePharma PLC.